Blog – Clinical Trial Results

Dr. Kevin Alexander and Dr. C. Michael Gibson discuss: Durable Survival Benefits of Acoramidis over 54Months in Variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Includingp.V142I: Interim Findings from ATTRibute-CM and its Open-Label Extension

September 17, 2026

Sponsored by an independent educational grant from BridgeBio Inc.

Dr. Oyvind Lie and Dr. C. Michael Gibson discuss: ACASA-TAVI : Antithrombotic therapy after TAVI

September 15, 2026

Disclosures: TBS

Dr. Matthew Reed and Dr. C. Michael Gibson discuss: ASPIRED: Multi-centre open label randomised controlled trial of immediate enhanced ambulatory ECG monitoring versus standard monitoring in acute unexplained syncope patients

September 11, 2026

Disclosures: TBD

Dr. Maria Back and Dr. C. Michael Gibson discuss: Remote Exercise SWEDEHEART: a cluster randomized cross-over trial on cardiac telerehabilitation

September 10, 2026

Disclosures: TBD

Dr. Jonathon Leipsic and Dr. C. Michael Gibson discuss: Reproducibility of AI-Informed Coronary Computed Tomography Angiography–Derived Coronary Plaque Volume Quantification

September 9, 2026

Sponsored by Heartflow

The intersection of cancer care and cardiovascular health is rapidly evolving. Dr. Novi Yanti Sari and Dr. C. Michael Gibson discuss key developments, emerging therapies, and what’s next for the field

September 1, 2026

Disclosures: TBD

Dr. Viktor Kocka and Dr. Josef Kroupa and Dr. C. Michael Gibson discuss: Prague 26: catheter-directed thrombolysis for pulmonary embolism

August 31, 2026

Disclosures: TBD

Dr. Lente Pol and Dr. C. Michael Gibson discuss: CAG after OHCA without ST-elevation

August 31, 2026

Disclosures: TBD

Dr. Sten Rubertsson and Dr. C. Michael Gibson discuss: DISCO trial: Acute coronary angiography after resuscitated out-of-hospital cardiac arrest without ST-elevation on the ECG

August 31, 2026

Disclosures: TBD

Dr. Keyur Vora and Dr. C. Michael Gibson discuss: Intravenous Dexrazoxane for Hemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial (SHIELD-MI)

August 31, 2026

Disclosures: TBD